¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"turn down ratio"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • birth-death ratio
    Ãâ»ý»ç¸Áºñ
  • blood urea nitrogen/creatinine ratio
    Ç÷¾×¿ä¼ÒÁú¼Ò/Å©·¹¾ÆÆ¼´Ñºñ
  • body-weight ratio
    üÁß½ÅÀåºñ
  • breathing reserve ratio
    ȯ±â¿¹ºñºñ
  • common ratio
    °øºñ
  • contrast enhancement ratio
    Á¶¿µÁõ°­ºñ
  • contrast to noise ratio
    ´ëÁ¶´ëÀâÀ½ºñ
  • correlation ratio
    »ó°üºñ
  • cumulative incidence ratio
    ´©Àû¹ß»ýºñ
  • cup-disc ratio
    À¯µÎÇÔ¸ôºñ
  • cardiothoracic ratio
    ½ÉÀå°¡½¿ºñ, ½ÉÈäºñ
  • cell color ratio
    ÀûÇ÷±¸»ö¼Òºñ
  • caliber ratio
    1. Ç÷°ü°æºñÀ² 2. ±¸°æºñÀ²
  • charge to mass ratio
    ÀüÇÏ´ëÁú·®ºñ
  • child-woman ratio
    ¸ð¾ÆºñÀ²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • albumin-globulin ratio
    ¾ËºÎ¹Î±Û·ÎºÒ¸°ºñ
  • arm ratio
    µÎÆÈºñ
  • axial ratio
    Ãàºñ
  • benefit/risk ratio
    À¯ÀÍÀ¯ÇغñÀ²
  • birth-death ratio
    Ãâ»ý»ç¸Áºñ
  • blood urea nitrogen/creatinine ratio
    Ç÷¾×´¢¼ÒÁú¼ÒÅ©·¹¾ÆÆ¼´Ñºñ
  • body-weight ratio
    üÁß½ÅÀåºñ, ¸ö¹«°ÔŰºñ
  • breathing reserve ratio
    ȯ±â¿¹ºñºñ
  • caliber ratio
    Ç÷°ü°æºñ
  • cardiothoracic ratio
    ½ÉÀå°¡½¿ºñ, ½ÉÈäºñ
  • cell color ratio
    ÀûÇ÷±¸»ö¼Òºñ
  • charge to mass ratio
    ÀüÇÏ´ëÁú·®ºñ
  • child-woman ratio
    ¸ð¾ÆºñÀ²
  • common ratio
    °øºñ
  • contrast enhancement ratio
    Á¶¿µÁõ°­ºñ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • V/Q => ventilation/perfusion ratio
    ȯ±â/°ü·ùºñ
  • VA/Q => ventilation/perfusion ratio
    ȯ±â/°ü·ù ºñ
  • air entrainment ratio
    °ø±âÀ¯ÀÔ·ü.
  • air pollution ratio
    ´ë±â¿À¿°·ü(ÊÙËô).
  • albumin CSF/serum ratio
    ¾ËºÎ¹Î ³úô¼ö¾×/Ç÷û ºñ
  • albumin-globulin ratio =A£¯G r.
    ¾ËºÎ¹Î ±Û·ÎºÒ¸°ºñ.
  • albumin/globulin ratio
    ¾ËºÎ¹Î/±Û·ÎºÒ¸° ºñ
  • alpha/beta (¥á/¥â) ratio
    ¥á/¥â ºñ
  • arm ratio
    µÎÆÈºñ(¡­Ýï).
  • gas exchange ratio
    °¡½º±³È¯ºñÀ²(ÎßüµÝï×Ë).
  • gyromagnetic ratio
    ȸÀü Àڱ⠺ñÀ²
  • heart lung ratio =HLR
    ½ÉÆó°è¼ö(ãýøËÌõâ¦), ½ÉÈä(°û)ºñ(ãýýØÎ¬Ýï).
  • hydrodynamic ratio
    ¼ö·ÂÇÐ(Àû) ºñÀ²
  • immunoglobulin G CSF/serum ratio
    ¸é¿ª±Û·ÎºÒ¸° G ³úô¼ö¾×/Ç÷û ºñ(À²)
  • innervation ratio
    ½Å°æÁö¹èºñ(¡­Ýï).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • down phenomenon
  • down regulation
    ÇÏÇâÁ¶Àý
  • down syndrome
    ´Ù¿îÁõÈıº(¡­ñøý¦ÏØ)
  • down-regulation (of receptors)
    (¼ö¿ëü)ÇÏÇâÁ¶Àý.
  • down-regulation (of receptors)
    ¼ö¿ëü(áôé»ô÷)ÇÏÇâÁ¶Àý(ù»ú¾ðàï½).
  • face down position
    º¹¿ÍÀ§.
  • mongolism =Down s syndrome
    ¸ù°íÁõ(ÙÕ Í¯ñø).
  • mongolism =down s syndrome
    ¸ù°íÁõ(ÙÕͯñø)
  • prism base-down
    ¹Ù´Ú¾Æ·¡ÇÁ¸®Áò
  • ring down
    ¿©¿î
  • ring down time
    ¿©¿î ½Ã°£ (æ®ê¤ ãÁÊà)
  • ring down time
    ¿©¿î ½Ã°£)
  • step down transformer
    °­¾Ðº¯¾Ð±â(˽äâܨäâÐï).
  • step-down heating
    ´Ü°èº°°¨¿Â
  • syndrome (down)
    ÁõÈıº (´Ù¿îÁõÈıº)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • base ratio
    ¿°±âºñ(ç¤ÐñÝï)
  • channels ratio method
    ä³Î ºñÀ²¹ý(Ýï×ËÛö)
  • coding ratio
    ºÎÈ£ºñ(ݬûÜÝï)
  • dichroic ratio
    ÀÌ»öºñ(ì£ßäÝï)
  • disequilibrium ratio
    ºÒÆòÇü ºñÀ²(ÝÕøÁû¬Ýï×Ë)
  • dissymmetry ratio
    ºÒ¿ÏÀü´ëĪ ºñÀ²(ÝÕèÇîïÓßöàÝï×Ë)
  • distribution ratio
    "ºÐÆ÷À²(ÝÂøÖëÒ), (ÔÒ) partition coefficient"
  • Donnan ratio
    µ·³­ À²(ëÒ)
  • extraction ratio
    ÃßÃâºñ(õÎõóÝï)
  • flux ratio method
    Çöô½º ºñÀ²¹ý(Ýï×ËÛö)
  • frictional ratio
    ¸¶Âûºñ(ؤóÍÝï)
  • G + C/A + T ratio
    G + C/A + T ºñ(Ýï)
  • gyromagnetic ratio
    ÀÚ±âȸÀü ºñ(í¸Ñ¨üÞï®Ýï)
  • ratio
    ºñÀ²(Ýï×Ë)
  • induction ratio
    À¯µµºñ(ë¯ÓôÝï)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • uptake ratio
    ¼·ÃëÀ²
  • velocity ratio
    ¼Óµµºñ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TCH tanned-cell hemagglutination; thiophen-2-carboxylic acid hydrazide; total circulating hemoglobin; tu...
TCR T-cell reactivity; T-cell receptor; T-cell rosette; thalamocortical relay; total cytoplasmic ribosom...
TEF Tracheo-Esophageal Fistula
  ? Tx
    1. Infant Warmer
 ...
BD barbital-dependent; barbiturate dependence; base deficit; base of prism down; basophilic degeneratio...
CAGE cut down, annoyed by criticism, guilty about drinking, eye-opener drinks (a test for alcoholism)
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HDT Head Down Tilt
SDH Step-down heating
HDBR head down bed rest
L/S ratio Lecithin/sphingomyelin ratio
APC SR APC sensitivity ratio
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • air entrainment ratio
    °ø±â À¯ÀÔ·ü
  • benefit/risk ratio
    À¯ÀÍ/À¯ÇØ ºñÀ²
  • body-weight ratio
    üÁß ½ÅÀå ºñ
  • cardiothoracic ratio
    ½ÉÈäºñ, ½ÉÈä°û ºñ, ½ÉÈä °è¼ö
  • cell color ratio
    Ç÷±¸»ö¼Òºñ, ÀûÇ÷±¸ »ö¼Òºñ
  • child woman ratio
    ¸ð¾Æ ºñÀ²
  • crown-root ratio
    Ä¡°ü´ë Ä¡±Ùºñ
  • curative ratio
    Ä¡À¯À²
  • death ratio
    »ç¸Áºñ
    µ¿ÀǾî=
  • effective ratio
    À¯È¿À²
    ¾î´À ÇѰè±îÁö´Â ¾àÁ¦ ¿ë·®°ú À¯È¿À²Àº ºñ·ÊÇÑ´Ù. ÇѰè À̻󿡼­´Â ºÎÀÛ¿ëÀÌ ³ªÅ¸³­´Ù.
  • expansion ratio
    ÆØÃ¢ºñ
  • innervation ratio
    ½Å°æ Áö¹è ºñ
  • magnetization transfer ratio
    ÀÚÈ­ Àü´Þ ºñÀ²
  • mercuryalloy ratio
    ¼öÀº Çձݺñ
  • monocyte lymphocyte ratio
    ´Ü±¸ ¸²ÇÁ±¸ºñ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
down promoter mutation <molecular biology> A mutation (a change in base pair sequence) in a promoter region, this results in lower gene expression (less transcription of the gene occurs).
(09 Oct 1997)
down-regulation <physiology> Development of a refractory or tolerant state consequent upon repeated administration of a pharmacologically or physiologically active substance.
It is the process that decreases ligand and receptor interactions or reduces the responsiveness of a cell to a stimulus following first exposure.
This is often accompanied by an initial decrease in affinity of receptors for the agent and a subsequent reduction in the number of available receptors expressed on the surface which can result from internalisation of the ligand:receptor complex or from decreased expression of the receptor.
Classically the concept referred to hormone receptors but contemporary usage includes other cell surface receptors.
(03 Jul 1999)
Down's syndrome <genetics, syndrome> A congenital disorder in which a person is born with three copies of chromosome 21 (trisomy 21).
Clinical features include moderate to severe mental retardation, slanting eyes, a broad short skull, broad hands and short fingers. Other congenital abnormalities include heart defects, oesophageal atresia and an increased incidence of acute lymphocytic leukaemia.
Trisomy 21 can be detected in the first few months of pregnancy by amniocentesis. Risk factors include prior child with Down's syndrome and mothers who become pregnant after age 40. This disorder was formerly known as mongolism.
Incidence: 1 in 1000 births.
(09 Oct 1997)
down syndrome <radiology> Trisomy 21, mongolism, atlantoaxial subluxation, Wormian bones, absent/small paranasal sinuses, endocardial cushion (AV canal) defects, aberrant right subclavian artery, 2 ossification centres for manubrium (90%), 11 or 13 ribs, duodenal atresia / stenosis, tracheo-oesophageal fistula, Hirschsprung disease
(12 Dec 1998)
let-down reflex <neurology, paediatrics> An involuntary reflex during breast feeding which causes the milk to flow freely.
See: milk-ejection reflex
(22 Sep 2002)
absolute terminal innervation ratio The number of motor endplates divided by the number of terminal axons related to them.
(05 Mar 2000)
accommodative convergence-accommodation ratio The amount of convergence (measured in prism diopters of convergence) divided by the amount of accommodation (measured in diopters) required to direct both eyes upon an object.
(05 Mar 2000)
A/G ratio <abbreviation> Albumin-globulin ratio.
(05 Mar 2000)
albumin-globulin ratio The ratio of albumin to globulin in the serum or in the urine in kidney disease; the normal ratio in the serum is approximately 1.55.
(05 Mar 2000)
ALT:AST ratio The ratio of serum alanine aminotransferase to serum aspartate aminotransferase; elevated serum levels of both enzymes characterise hepatic disease; when both levels are abnormally elevated and the ALT:AST ratio is greater than 1.0, severe hepatic necrosis or alcoholic hepatic disease is likely; when the ratio is less than 1.0, an acute non-alcoholic hepatic condition is favoured.
(05 Mar 2000)
amylase-creatinine clearance ratio A test for the diagnosis of acute pancreatitis; it is determined by measuring amylase and creatinine in serum and urine in apparently healthy individuals the renal clearance of amylase is less than 5% that of creatinine; in acute pancreatitis the ratio is said to be greater than 0.05 or 5%.
(05 Mar 2000)
aspect ratio <radiobiology> In toroidal geometry, the ratio of the major diameter (total width of the torus) to the minor diameter (width of a slice taken through one side of the ring). In inertial-confinement fusion, aspect ratio refers to the ratio of a fuel pellet's radius to its wall thickness.
(09 Oct 1997)
at/gc ratio <molecular biology> The ratio of adenine-thymine base pairs to guanine-cytosine base pairs on a DNA molecule.
(09 Oct 1997)
basic reproductive rate, ratio <epidemiology> See Reproductive Ratio.
(05 Dec 1998)
body-weight ratio Body weight (in grams) divided by stature (in centimeters).
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • risk-benefit ratio
    À§Ç輺°ú ¼öÀͼº°úÀÇ ºñÀ²
  • in one's turn
    Â÷·Ê¿¡ µû¶ó
  • turn
    µ¹(¸®)´Ù,ÇâÇÏ´Ù,ȸÀü,º¯È­,¼ø¹ø
  • turn aside
    ±æÀ»À߸øµé´Ù; ¿Ü¸éÇÏ´Ù; ºñŰ´Ù
  • turn in
    Á¦ÃâÇÏ´Ù; Á¢´Ù; ¹ÝȯÇÏ´Ù
  • turn off
    »ý»êÇÏ´Ù; ÇØ°íÇÏ´Ù; ²ô´Ù
  • turn on
    Ʋ¾î¼­ ³ª¿À°ÔÇÏ´Ù; °ø°ÝÇÏ´Ù
  • turn out
    »ý»êÇÏ´Ù;²ô´Ù;ÇØ°íÇÏ´Ù;µÚÁý´Ù
  • turn over
    °í°´ÀÇ µå³ªµë
  • turn to
    ¹®ÀÇÇÏ´Ù; ã¾Æº¸´Ù; ÀÇÁ¸ÇÏ´Ù
  • turn up
    À§ ÂÊÀ» ÇâÇϰÔÇÏ´Ù
  • counter-rocking-turn
    ¿ªÈ¸Àü;Ä«¿îÅÍ
  • good turn
    ¼±Çà;Ä£ÀýÇÑ ÇàÀ§;È£ÀÇ
  • hand's turn
    (¾à°£ÀÇ)³ë·Â;Á¶·Â;°Åµé¾î ÁÜ;µµ¿Í ÁÜ
  • right turn
    ¸öÀ» ¿ìÃøÀ¸·Î 90µµ ¹æÇâÀüȯÇϱâ;=RIGHT FACE
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á